Thyreos provides prophylactic vaccines for neuroinvasive herpesvirus infections.
Thyreos has raised $1.0M in total funding. The most recent round was Seed. The last funding was announced in December 2022.
Thyreos's investors include Invest Nebraska, National Institute of Food and Agriculture.
Thyreos is headquartered in Lincoln, United States.
Thyreos provides prophylactic vaccines for neuroinvasive herpesvirus infections.
Thyreos is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Thyreos — Funding & Investors." VCBacked, December 12, 2022, https://www.vcbacked.co/company/thyreos. Accessed September 30, 2026.
VCBacked. (2022). Thyreos — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/thyreos
{{cite web |title=Thyreos — Funding & Investors |url=https://www.vcbacked.co/company/thyreos |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated